KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $827.1 million.

  • Royalty Pharma's Cash from Operations rose 1139.67% to $827.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 billion, marking a year-over-year decrease of 1008.18%. This contributed to the annual value of $2.5 billion for FY2025, which is 1008.18% down from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's Cash from Operations is $827.1 million, which was up 1139.67% from $702.6 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Cash from Operations registered a high of $1.0 billion during Q1 2023, and its lowest value of $364.0 million during Q2 2025.
  • For the 5-year period, Royalty Pharma's Cash from Operations averaged around $620.4 million, with its median value being $585.5 million (2022).
  • As far as peak fluctuations go, Royalty Pharma's Cash from Operations surged by 12461.53% in 2023, and later plummeted by 4470.08% in 2025.
  • Over the past 5 years, Royalty Pharma's Cash from Operations (Quarter) stood at $490.0 million in 2021, then grew by 16.32% to $569.9 million in 2022, then soared by 35.57% to $772.6 million in 2023, then fell by 3.9% to $742.5 million in 2024, then increased by 11.4% to $827.1 million in 2025.
  • Its Cash from Operations stands at $827.1 million for Q4 2025, versus $702.6 million for Q3 2025 and $364.0 million for Q2 2025.